[
    [
        {
            "time": "2021-05-09",
            "original_text": "复星医药拟成立合资公司，在中国生产mRNA 新冠疫苗",
            "features": {
                "keywords": [
                    "复星医药",
                    "mRNA",
                    "新冠疫苗",
                    "合资公司"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药拟成立合资公司，在中国生产mRNA 新冠疫苗",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-05-09",
            "original_text": "公告精选：复星医药子公司拟与BioNTech设合资公司；龙蟒佰利上调钛白粉售价",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "合资",
                    "钛白粉",
                    "龙蟒佰利"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "化工"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "公告精选：复星医药子公司拟与BioNTech设合资公司；龙蟒佰利上调钛白粉售价",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-09",
            "original_text": "复星医药(02196)：复星医药产业与BioNTech拟就新冠疫苗产品的本地化生产及商业化设立合资公司",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "新冠疫苗",
                    "本地化生产",
                    "商业化"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196)：复星医药产业与BioNTech拟就新冠疫苗产品的本地化生产及商业化设立合资公司",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-05-09",
            "original_text": "复星医药(02196.HK)子公司拟与BioNTech设立合资公司实现新冠疫苗产品本地化生产及商业化",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "新冠疫苗",
                    "本地化生产",
                    "商业化"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)子公司拟与BioNTech设立合资公司实现新冠疫苗产品本地化生产及商业化",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-05-09",
            "original_text": "新冠疫苗专利将开放?产能受限难救急，国内疫苗企业扩产稳为上",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "专利开放",
                    "产能受限",
                    "扩产"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "新冠疫苗专利将开放?产能受限难救急，国内疫苗企业扩产稳为上",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-05-09",
            "original_text": "上海区域股市周报：澜起科技市值缩水最多 复星医药进入上海股市值前10强 连续下跌",
            "features": {
                "keywords": [
                    "复星医药",
                    "上海股市",
                    "市值",
                    "连续下跌"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "上海区域股市周报：澜起科技市值缩水最多 复星医药进入上海股市值前10强 连续下跌",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]